PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
DAWN vs. SPRY
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between DAWN and SPRY is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

DAWN vs. SPRY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Day One Biopharmaceuticals, Inc. (DAWN) and Silverback Therapeutics Inc (SPRY). The values are adjusted to include any dividend payments, if applicable.

-20.00%-10.00%0.00%10.00%20.00%30.00%SeptemberOctoberNovemberDecember2025February
-11.78%
-13.26%
DAWN
SPRY

Key characteristics

Sharpe Ratio

DAWN:

-0.32

SPRY:

0.79

Sortino Ratio

DAWN:

-0.14

SPRY:

1.42

Omega Ratio

DAWN:

0.98

SPRY:

1.17

Calmar Ratio

DAWN:

-0.28

SPRY:

0.56

Martin Ratio

DAWN:

-0.78

SPRY:

2.81

Ulcer Index

DAWN:

21.31%

SPRY:

17.62%

Daily Std Dev

DAWN:

51.93%

SPRY:

63.11%

Max Drawdown

DAWN:

-79.51%

SPRY:

-95.20%

Current Drawdown

DAWN:

-55.48%

SPRY:

-81.39%

Fundamentals

Market Cap

DAWN:

$1.25B

SPRY:

$1.09B

EPS

DAWN:

-$0.97

SPRY:

-$0.50

Total Revenue (TTM)

DAWN:

$101.95M

SPRY:

$2.57M

Gross Profit (TTM)

DAWN:

$99.54M

SPRY:

$2.43M

EBITDA (TTM)

DAWN:

-$151.63M

SPRY:

-$50.25M

Returns By Period

In the year-to-date period, DAWN achieves a -1.89% return, which is significantly lower than SPRY's 6.54% return.


DAWN

YTD

-1.89%

1M

0.40%

6M

-11.78%

1Y

-14.63%

5Y*

N/A

10Y*

N/A

SPRY

YTD

6.54%

1M

-17.05%

6M

-13.27%

1Y

47.89%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

DAWN vs. SPRY — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DAWN
The Risk-Adjusted Performance Rank of DAWN is 3030
Overall Rank
The Sharpe Ratio Rank of DAWN is 3030
Sharpe Ratio Rank
The Sortino Ratio Rank of DAWN is 2929
Sortino Ratio Rank
The Omega Ratio Rank of DAWN is 2929
Omega Ratio Rank
The Calmar Ratio Rank of DAWN is 3030
Calmar Ratio Rank
The Martin Ratio Rank of DAWN is 3030
Martin Ratio Rank

SPRY
The Risk-Adjusted Performance Rank of SPRY is 7070
Overall Rank
The Sharpe Ratio Rank of SPRY is 7272
Sharpe Ratio Rank
The Sortino Ratio Rank of SPRY is 6969
Sortino Ratio Rank
The Omega Ratio Rank of SPRY is 6767
Omega Ratio Rank
The Calmar Ratio Rank of SPRY is 7070
Calmar Ratio Rank
The Martin Ratio Rank of SPRY is 7272
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

DAWN vs. SPRY - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Day One Biopharmaceuticals, Inc. (DAWN) and Silverback Therapeutics Inc (SPRY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for DAWN, currently valued at -0.32, compared to the broader market-2.000.002.00-0.320.79
The chart of Sortino ratio for DAWN, currently valued at -0.14, compared to the broader market-4.00-2.000.002.004.006.00-0.141.42
The chart of Omega ratio for DAWN, currently valued at 0.98, compared to the broader market0.501.001.502.000.981.17
The chart of Calmar ratio for DAWN, currently valued at -0.28, compared to the broader market0.002.004.006.00-0.280.63
The chart of Martin ratio for DAWN, currently valued at -0.78, compared to the broader market-10.000.0010.0020.0030.00-0.782.81
DAWN
SPRY

The current DAWN Sharpe Ratio is -0.32, which is lower than the SPRY Sharpe Ratio of 0.79. The chart below compares the historical Sharpe Ratios of DAWN and SPRY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.002.004.006.00SeptemberOctoberNovemberDecember2025February
-0.32
0.79
DAWN
SPRY

Dividends

DAWN vs. SPRY - Dividend Comparison

Neither DAWN nor SPRY has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

DAWN vs. SPRY - Drawdown Comparison

The maximum DAWN drawdown since its inception was -79.51%, smaller than the maximum SPRY drawdown of -95.20%. Use the drawdown chart below to compare losses from any high point for DAWN and SPRY. For additional features, visit the drawdowns tool.


-75.00%-70.00%-65.00%-60.00%-55.00%-50.00%-45.00%-40.00%SeptemberOctoberNovemberDecember2025February
-55.48%
-68.09%
DAWN
SPRY

Volatility

DAWN vs. SPRY - Volatility Comparison

The current volatility for Day One Biopharmaceuticals, Inc. (DAWN) is 11.01%, while Silverback Therapeutics Inc (SPRY) has a volatility of 15.95%. This indicates that DAWN experiences smaller price fluctuations and is considered to be less risky than SPRY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%SeptemberOctoberNovemberDecember2025February
11.01%
15.95%
DAWN
SPRY

Financials

DAWN vs. SPRY - Financials Comparison

This section allows you to compare key financial metrics between Day One Biopharmaceuticals, Inc. and Silverback Therapeutics Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab